Silvia de Muga

640 citations

15 papers · 479 indexed · h-index 12

Co-authors: Josep Lloreta Sílvia Hernández José A. Lorente Sérgio Serrano Laia Agell Marta Lorenzo Núria Juanpere Marta Salido
Topics: Prostate Cancer Treatment and Research (7 papers)Bladder and Urothelial Cancer Treatments (5 papers)PI3K/AKT/mTOR signaling in cancer (4 papers)
Cited by: Cancer Research Pulmonary and Respiratory Medicine Oncology
Journals: PLoS ONE American Journal Of Pathology Annals of Oncology
Partner nations: Spain United States Germany

In The Last Decade

Silvia de Muga

15 papers receiving 469 citations

Peers

Countries citing papers authored by Silvia de Muga

Since Specialization

Citations

This map shows the geographic impact of Silvia de Muga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia de Muga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia de Muga more than expected).

Fields of papers citing papers by Silvia de Muga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia de Muga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia de Muga. The network helps show where Silvia de Muga may publish in the future.

Co-authorship network of co-authors of Silvia de Muga

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia de Muga. A scholar is included among the top collaborators of Silvia de Muga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia de Muga. Silvia de Muga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC 2019 ·OncoImmunology ·Roberto Martínez,Gustavo Tapia,Silvia de Muga,(unknown),María González Cao,Cristina Teixidó,Víctor Urrea,Elisabet García,(unknown),L. Ibarz,Julià Blanco,Bonaventura Clotet,Cecilia Cabrera	27
2	FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression 2017 ·Human Pathology ·Josep Lloreta,Alba Font‐Tello,Núria Juanpere,Albert Francés,Marta Lorenzo,Lara Nonell,Silvia de Muga,Ivonne Vázquez,Lluís Cecchini,(unknown)	17
3	ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression 2017 ·Oncotarget ·(unknown),Núria Juanpere,Silvia de Muga,Marta Lorenzo,Joan Gil,Alba Font‐Tello,Laia Agell,(unknown),(unknown),José Luís Merino,Laia Serrano,Lluís Fumadó,Lluís Cecchini,Josep Lloreta	16
4	ConcurrentTMPRSS2-ERGandSLC45A3-ERGrearrangements plusPTENloss are not found in low grade prostate cancer and define an aggressive tumor subset 2016 ·The Prostate ·Sílvia Hernández,Alba Font‐Tello,Núria Juanpere,Silvia de Muga,Marta Lorenzo,Marta Salido,Lluís Fumadó,Laia Serrano,Lluís Cecchini,Sérgio Serrano,Josep Lloreta	16
5	HER2 as a target in invasive urothelial carcinoma 2015 ·Cancer Medicine ·Joaquim Bellmunt,Lillian Werner,Aristotle Bamias,André P. Fay,Rachel S. Park,Markus Riester,Shamini Selvarajah,Justine A. Barletta,David M. Berman,Silvia de Muga,Marta Salido,Enrique Gallardo,Federico Rojo,Elizabeth A. Guancial,Richard Bambury,Stephanie A. Mullane,Toni K. Choueiri,Massimo Loda,Edward C. Stack,Jonathan E. Rosenberg	43
6	Association of ERG and TMPRSS2‐ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels 2015 ·The Prostate ·Alba Font‐Tello,Núria Juanpere,Silvia de Muga,Marta Lorenzo,José A. Lorente,Lluís Fumadó,Laia Serrano,Sérgio Serrano,Josep Lloreta,Sílvia Hernández	53
7	Ros1 Rearrangements and Copy Number Alterations in Nsclc Patients: High Frequency of Ros1 Deletions 2014 ·Annals of Oncology ·Sergi Clavé,Javier Gimeno,Silvia de Muga,Lara Pijuán,Joana Vidal,Marta Lorenzo,Sílvia Menéndez,Álvaro Taus,Ana M Muñoz‐Mármol,Enric Carcereny,Noemı́ Reguart,José Luís Mate,S. Serrano,Joan Albanell,Blanca Espinet,Edurne Arriola,Marta Salido	1
8	Identification of ALK Gene Alterations in Urothelial Carcinoma 2014 ·PLoS ONE ·Joaquim Bellmunt,Shamini Selvarajah,Scott J. Rodig,Marta Salido,Silvia de Muga,Irmgard Costa,Beatríz Bellosillo,Lillian Werner,Stephanie A. Mullane,André P. Fay,Robert O’Brien,Jordi Barretina,André E. Minoche,Sabina Signoretti,Clara Montagut,Heinz Himmelbauer,David M. Berman,Philip W. Kantoff,Toni K. Choueiri,Jonathan E. Rosenberg	11
9	CXCR4 mRNA overexpression in high grade prostate tumors: Lack of association with TMPRSS2-ERG rearrangement 2013 ·Cancer Biomarkers ·Silvia de Muga,Sílvia Hernández,Marta Salido,Marta Lorenzo,Laia Agell,Núria Juanpere,José A. Lorente,Sérgio Serrano,Josep Lloreta	11
10	A 12-Gene Expression Signature Is Associated with Aggressive Histological in Prostate Cancer 2012 ·American Journal Of Pathology ·Laia Agell,Sílvia Hernández,Lara Nonell,Marta Lorenzo,Eulàlia Puigdecanet,Silvia de Muga,Núria Juanpere,Raquel Bermudo,Pedro L. Fernández,José A. Lorente,Sérgio Serrano,Josep Lloreta	40
11	Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer 2012 ·Human Pathology ·Núria Juanpere,Laia Agell,Marta Lorenzo,Silvia de Muga,Laura López-Vilaró,(unknown),Sergi Mojal,Sérgio Serrano,José A. Lorente,Josep Lloreta,Sílvia Hernández	48
12	Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas 2010 ·Modern Pathology ·Silvia de Muga,Sílvia Hernández,Laia Agell,Marta Salido,Núria Juanpere,Marta Lorenzo,José A. Lorente,Sérgio Serrano,Josep Lloreta	54
13	PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events 2010 ·Modern Pathology ·Laia Agell,Sílvia Hernández,Marta Salido,Silvia de Muga,Núria Juanpere,Montserrat Arumí-Uría,Sílvia Menéndez,Marta Lorenzo,José A. Lorente,Sérgio Serrano,Josep Lloreta	41
14	FGFR3 mutations in prostate cancer: association with low-grade tumors 2009 ·Modern Pathology ·Sílvia Hernández,Silvia de Muga,Laia Agell,Núria Juanpere,Raquel Esgueva,José A. Lorente,Sergi Mojal,Sérgio Serrano,Josep Lloreta	61
15	KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations 2008 ·Modern Pathology ·Laia Agell,Sílvia Hernández,Silvia de Muga,José A. Lorente,Núria Juanpere,Raquel Esgueva,Sergi Serrano,Antoni Gelabert,Josep Lloreta	40

About Silvia de Muga

Silvia de Muga is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Immunology and Allergy, having authored 15 papers that have together received 479 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (7 papers), Bladder and Urothelial Cancer Treatments (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). The work is most often cited by research in Cancer Research (149 citations), Pulmonary and Respiratory Medicine (201 citations) and Oncology (112 citations). Silvia de Muga has collaborated with scholars based in Spain, United States and Germany. Frequent co-authors include Josep Lloreta, Sílvia Hernández, José A. Lorente, Sérgio Serrano, Laia Agell, Marta Lorenzo, Núria Juanpere, Marta Salido, Raquel Esgueva and Sergi Mojal. Their work appears in journals such as PLoS ONE, American Journal Of Pathology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact